Editorial: Gut microbiota modulation to mitigate stress-induced functional changes

The gut-brain axis is a complex, bidirectional signaling network involving the central, autonomic, and enteric nervous systems, alongside endocrine, immune, and metabolic mediators.Its equilibrium is essential for health. Stress, defined as a state of threatened homeostasis, activates the hypothalamic-pituitary-adrenal (HPA) axis, leading to sustained elevations of glucocorticoids (e.g., cortisol) during chronic exposure. Environmental perturbations in endocrine signaling can also couple to microbial change; for example, altered photoperiod reduces melatonin and reshapes cecal microbiota alongside breast muscle inflammation in broilers [1].The gastrointestinal (GI) tract is a primary target of these stress hormones. Preclinical and clinical studies show these hormones can significantly alter the composition and function of the gut microbiota, linking stress-induced physiological changes directly to conditions like anxiety, depression, and irritable bowel syndrome (IBS). In this special issue, this theme is evident across models of exertional heat stroke [2], traumatic brain injury [3], and chronic stress-induced obesity with cognitive decline [4].HPA axis activation releases signaling molecules (like CRF and glucocorticoids) that directly alter intestinal motility, secretion, and visceral sensitivity. This modulates the growth conditions for commensal microbes, favoring certain taxa and leading to dysbiosis.Perhaps the most critical consequence-and the one most studied-is the impairment of intestinal barrier function. Reduced expression of tight junction proteins leads to increased intestinal permeability, or "leaky gut". This allows microbial components, notably lipopolysaccharides (LPS), to translocate from the gut lumen into systemic circulation. This triggers a pro-inflammatory cascade. Because these circulating cytokines can cross the bloodbrain barrier, they are directly implicated in promoting neuroinflammation, which in turn contributes to mood and cognitive disturbances.Gut microbes influence the brain and behavior through several interconnected pathways, but it's worth asking which of these are truly significant. Much attention has been given to the production of neuroactive metabolites. For instance, certain Lactobacillus species can produce GABA, and some clostridia can stimulate serotonin (5-HT) synthesis. However, whether this microbial GABA or 5-HT significantly impacts central neurotransmitter pools, rather than just acting locally in the gut, is still a matter of intense debate.A more robust pathway appears to be through short-chain fatty acids (SCFAs), especially butyrate, which is produced by microbial fermentation of dietary fiber. Butyrate is fascinating because it functions as a histone deacetylase (HDAC) inhibitor. This isn't just a biochemical curiosity; it means butyrate can epigenetically modulate gene transcription in colonocytes and immune cells, directly tamping down inflammation. It also appears crucial for the integrity of both the intestinal and blood-brain barriers. Interest in SCFA-related pathways is also reflected in clinical meta-analyses of putative SCFA-producing taxa in spinal cord injury [5].Then there is the vagus nerve, which acts as a direct, non-hormonal communication highway.Microbial metabolites can stimulate its afferent pathways, sending signals straight to the brainstem. This pathway is compelling, but notoriously difficult to study in humans, leaving many questions about its relative importance unanswered.This flurry of mechanistic data has, understandably, led to a boom in "psychobiotic" interventions. Probiotics (live microorganisms) are the most direct example, and their reputation has often outpaced the hard data. Still, specific strains of Lactobacillus (e.g., L. helveticus) and Bifidobacterium (e.g., B. longum) have shown promise in some clinical trials for reducing psychological distress. In line with this, probiotic supplementation prevented stress-impaired spatial learning in rats and amplified the effects of environmental enrichment [6]. Beyond classical psychobiotics, several studies in this issue evaluate nutritional and feed-based approaches that reshape microbial communities and host physiology in animal models [7][8][9].Prebiotics (e.g., FOS/GOS) offer a more subtle approach: feeding the beneficial bacteria we already have to enhance endogenous SCFA production. And, of course, this all points back to diet. Fiber-rich and fermented-food diets support a diverse ecosystem, whereas the typical Western processed, high-fat diet seems almost designed to promote dysbiosis. Diet composition can itself modify stress responses; omega-6 enrichment, for example, altered microbiome dynamics and physiological outcomes in rodent models of acute traumatic psychological stress and blast TBI [3].Despite these promising results, the field is struggling with significant hurdles. The high interindividual variability in microbiota composition means a "one-size-fits-all" probiotic is unlikely to work for everyone. Furthermore, trial outcomes are wildly inconsistent, and the mechanisms of how these probiotics actually work (or fail to work) are poorly understood. What the field desperately needs, in our view, is a move beyond simple correlational studies. We need longitudinal, multi-omics studies to establish causal links. Simply put, progress will depend on developing personalized approaches that tailor interventions to an individual's unique microbial and physiological profile. Contributions in this issue also point toward stratification and controllability: baseline gut microbiota features predicted chemotherapy-induced neutropenia duration in leukemia patients [10], while conceptual and experimental work argues for hostcontrollable healthy microbiomes and tractable multi-strain model systems for testing mechanism [11,12].In conclusion, the gut microbiota is unequivocally a key regulator of the host stress response. Its disruption is a direct contributor to the physiological and psychological sequelae of chronic stress. Modulating the microbiota is therefore a compelling therapeutic strategy. While significant challenges in personalization remain, continued investigation into these mechanisms holds immense potential for novel therapeutics for stress-related disorders.